TZT-1027 (Soblidotin)和吉西他滨联合治疗晚期或转移性实体瘤的I期研究，每3周给药1天和8天

The Internet Journal of Oncology Pub Date : 2007-12-31 DOI:10.5580/15d9

C. Verschraegen, H. Raftopoulos, K. Feit, R. Jager, Sang-Joon Lee, C. Sweeney

{"title":"TZT-1027 (Soblidotin)和吉西他滨联合治疗晚期或转移性实体瘤的I期研究，每3周给药1天和8天","authors":"C. Verschraegen, H. Raftopoulos, K. Feit, R. Jager, Sang-Joon Lee, C. Sweeney","doi":"10.5580/15d9","DOIUrl":null,"url":null,"abstract":"Background: TZT-1027 is a dolastatin 10 analog interfering with microtubule assembly, with increased antitumor activity when combined with gemcitabine in animal models. Patients and Methods: Eligible patients with refractory solid tumors received gemcitabine followed by TZT-1027 on Days 1 and 8 every 21 days, with pharmacokinetic sampling during the first 24 hours.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"11 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2007-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Phase I Study Of The Combination Of TZT-1027 (Soblidotin) And Gemcitabine Administered On Day 1 And 8 Every Three Weeks To Patients With Advanced Or Metastatic Solid Tumors\",\"authors\":\"C. Verschraegen, H. Raftopoulos, K. Feit, R. Jager, Sang-Joon Lee, C. Sweeney\",\"doi\":\"10.5580/15d9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: TZT-1027 is a dolastatin 10 analog interfering with microtubule assembly, with increased antitumor activity when combined with gemcitabine in animal models. Patients and Methods: Eligible patients with refractory solid tumors received gemcitabine followed by TZT-1027 on Days 1 and 8 every 21 days, with pharmacokinetic sampling during the first 24 hours.\",\"PeriodicalId\":22534,\"journal\":{\"name\":\"The Internet Journal of Oncology\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Internet Journal of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5580/15d9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Internet Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5580/15d9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

背景:TZT-1027是一种干扰微管组装的dolastatin 10类似物，在动物模型中与吉西他滨联合时具有增强的抗肿瘤活性。患者和方法:符合条件的难治性实体瘤患者在第1天和第8天每21天接受吉西他滨和TZT-1027治疗，并在前24小时进行药代动力学采样。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

A Phase I Study Of The Combination Of TZT-1027 (Soblidotin) And Gemcitabine Administered On Day 1 And 8 Every Three Weeks To Patients With Advanced Or Metastatic Solid Tumors

Background: TZT-1027 is a dolastatin 10 analog interfering with microtubule assembly, with increased antitumor activity when combined with gemcitabine in animal models. Patients and Methods: Eligible patients with refractory solid tumors received gemcitabine followed by TZT-1027 on Days 1 and 8 every 21 days, with pharmacokinetic sampling during the first 24 hours.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Internet Journal of Oncology

自引率

0.00%

发文量